(Hypertension. 2000;36:523.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Beneficial Renal and Hemodynamic Effects of Omapatrilat in Mild and Severe Heart Failure
From the Christchurch Cardioendocrine Research Group, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand.
Correspondence to Dr Richard Troughton, Department of Medicine, Christchurch Hospital, Riccarton Ave, PO Box 4345, Christchurch, New Zealand. E-mail richard.troughton{at}chmeds.ac.nz
Abstract—Omapatrilat is a member of the new drug class of vasopeptidase inhibitors that may offer benefit in the treatment of heart failure (HF) through simultaneous inhibition of angiotensin-converting enzyme and neutral endopeptidase. We examined the effects of omapatrilat in a placebo-controlled crossover study using a pacing model of HF. Seven sheep were paced sequentially at 180 bpm (mild HF) and then 225 bpm (severe HF) for 7 days each. Omapatrilat (0.005 mg/kg) or vehicle was administered by intravenous bolus on days 4 to 7 of each paced period. Omapatrilat lowered mean arterial and left atrial pressure and increased cardiac output acutely and chronically in both mild and severe HF (P<0.01 for all). Plasma atrial and brain natriuretic peptide and cGMP levels were stable acutely (P=NS), while brain natriuretic peptide increased after repeated dosing in severe HF (P<0.05). Plasma renin activity rose, whereas angiotensin II and aldosterone levels fell after acute and repeated dosing in both states (P<0.01 for all). Omapatrilat increased urinary sodium excretion by day 7 in both mild and severe HF (P<0.05). Effective renal plasma flow and glomerular filtration rate increased or were stable after omapatrilat in mild and severe HF after both acute and repeated dosing. Omapatrilat exhibited pronounced acute and sustained beneficial hemodynamic and renal effects in both mild and severe heart failure.
Key Words: vasopeptidase inhibitor • peptides • kidney • renin • angiotensin • aldosterone
This article has been cited by other articles:
 |
|
 |
|
  Z. A. Abassi, A. Yahia, S. Zeid, T. Karram, E. Golomb, J. Winaver, and A. Hoffman Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H722 - H728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Garwood Renal Insufficiency After Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2004; 8(3): 227 - 241. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Pfister, N. E. Martin, L. P. Haskell, and J. S. Barrett Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240 J. Clin. Pharmacol., June 1, 2004; 44(6): 621 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. McFarlane, N. Winer, and J. R. Sowers Role of the Natriuretic Peptide System in Cardiorenal Protection Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Richards Vasopeptidase inhibitors for heart failure: where do we go from here? Eur J Heart Fail, August 1, 2003; 5(4): 411 - 413. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Varagic, D. Susic, M. Slama, and E. D. Frohlich Omapatrilat Induces Profound Renal Vasodilation but Does Not Affect Coronary Hemodynamics Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 167 - 174. [Abstract] [PDF]
|
|
|
|
 |
|
 B. R. Palmer, A. P. Pilbrow, T. G. Yandle, C. M. Frampton, A. M. Richards, M. G. Nicholls, and V. A. Cameron Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction J. Am. Coll. Cardiol., March 5, 2003; 41(5): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Campbell Vasopeptidase Inhibition: A Double-Edged Sword? Hypertension, March 1, 2003; 41(3): 383 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dawson and A. D Struthers Review: Vasopeptidase inhibitors in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 156 - 159. [Abstract] [PDF]
|
|
|
|
|
|
F. Regamey, M. Maillard, J. Nussberger, H. R. Brunner, and M. Burnier Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men Hypertension, September 1, 2002; 40(3): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Packer, R. M. Califf, M. A. Konstam, H. Krum, J. J. McMurray, J.-L. Rouleau, K. Swedberg, and for the OVERTURE Study Group Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation, August 20, 2002; 106(8): 920 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cataliotti, G. Boerrigter, H. H. Chen, M. Jougasaki, L. C. Costello, T. Tsuruda, S.-C. Lee, L. S. Malatino, and J. C. Burnett Jr Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure Circulation, February 5, 2002; 105(5): 639 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Buschhausen, S. Seibold, O. Gross, T. Matthaeus, M. Weber, and E. Schulze-Lohoff Regulation of mesangial cell function by vasodilatory signaling molecules Cardiovasc Res, August 15, 2001; 51(3): 463 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ruschitzka, R. Corti, T. Quaschning, M. Hermann, and T. F. Luscher Vasopeptidase inhibitors--concepts and evidence Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1532 - 1535. [Full Text] [PDF]
|
|